Critical Diagnostics, makers of the Presage® ST2 Assay, today announced the addition of two key hires: Dennis Dalangin has joined the company as Vice President of Marketing, and Andrew Blidy as Project Manager for new product development. Both appointments are effective immediately.
Dennis comes to Critical Diagnostics from Alere Inc. (NYSE: ALR), where he was Global Director for the company’s anticoagulation solutions. Prior to Alere, he served as Manager, Global Marketing, at Philips Healthcare (NYSE: PHG). Dennis brings with him well over a decade of experience in the healthcare industry, with a focus on international marketing, product development, and direct and business-to-business activities.
Andrew joins Critical Diagnostics from Novartis where he worked in the company’s blood screening product line. Prior to Novartis (NYSE: NVS), he developed IVD products at Roche Molecular Systems (OTCQX: RHHBY), Applied Biosystems and Becton Dickinson Monoclonal Center (NYSE: BDX). Andrew brings well over 20 years of experience in the healthcare industry, with vast experience in research, product development, operations, manufacturing and project management functions.
“Dennis and Andrew are both incredibly talented individuals with extensive hands-on experience in the IVD field, and we are thrilled to have them join the team,” says CEO David Geliebter.
Both Dennis and Andrew will be based out of the Company’s headquarters in San Diego.
About Critical Diagnostics and ST2
Critical Diagnostics (www.criticaldiagnostics.com) develops novel biomarkers to help physicians optimize patient care in cardiovascular diseases, while containing healthcare costs. The Presage® ST2 Assay has been CE Marked and cleared by the US FDA. Critical Diagnostics has exclusive worldwide rights to ST2 for the diagnosis and prognosis of cardiovascular disease.